title: Chronic myelogenous leukemia.
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.forename: Ellin
authors.initials: E
authors.lastname: Berman
authors.forename: Kapil
authors.initials: K
authors.lastname: Bhalla
authors.forename: Edward A
authors.initials: EA
authors.lastname: Copelan
authors.forename: Marcel P
authors.initials: MP
authors.lastname: Devetten
authors.forename: Peter D
authors.initials: PD
authors.lastname: Emanuel
authors.forename: Harry P
authors.initials: HP
authors.lastname: Erba
authors.forename: Peter L
authors.initials: PL
authors.lastname: Greenberg
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Moore
authors.forename: Donna
authors.initials: D
authors.lastname: Przepiorka
authors.forename: Jerald P
authors.initials: JP
authors.lastname: Radich
authors.forename: Russell J
authors.initials: RJ
authors.lastname: Schilder
authors.forename: Paul
authors.initials: P
authors.lastname: Shami
authors.forename: B Douglas
authors.initials: BD
authors.lastname: Smith
authors.forename: David S
authors.initials: DS
authors.lastname: Snyder
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
authors.forename: Moshe
authors.initials: M
authors.lastname: Talpaz
authors.forename: Meir
authors.initials: M
authors.lastname: Wetzler
mesh_terms: D000465:Algorithms; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use / Q000633:toxicity; D001549:Benzamides; D002471:Cell Transformation, Neoplastic; D019457:Chromosome Breakage; D002892:Chromosomes, Human, Pair 22; D002899:Chromosomes, Human, Pair 9; D003561:Cytarabine / Q000627:therapeutic use; D020732:Cytogenetic Analysis; D018450:Disease Progression; D004347:Drug Interactions; D050939:Gene Fusion; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D000068877:Imatinib Mesylate; D007372:Interferons / Q000627:therapeutic use; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D010879:Piperazines / Q000627:therapeutic use / Q000633:toxicity; D017410:Practice Guidelines as Topic / Q000592:standards*; D011743:Pyrimidines / Q000627:therapeutic use / Q000633:toxicity; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism; D012074:Remission Induction; D055502:Secondary Prevention; D014178:Translocation, Genetic; D014184:Transplantation, Homologous
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D003561:Cytarabine; D000068877:Imatinib Mesylate; D007372:Interferons